Is Ortho Clinical Diagnostics part of J&J?

New Brunswick, NJ, June 30, 2014 — Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion, subject to customary adjustments.

Who is Ortho Clinical Diagnostics competitors?

Ortho Clinical Diagnostics’s top competitors include United Imaging Healthcare, Masimo, Tecan Group and Bio-Rad. Ortho Clinical Diagnostics is a company that provides in vitro diagnostics solutions to clinical laboratories and immunohematology communities.

Is Ortho Clinical Diagnostics a good company to work for?

Good company but expects long work weeks from employees I like the people at Ortho. They are very dedicated, loyal and hardworking individuals. I feel the management needs to do a better job of life/work balance issues and the amount of stress that is evident in the work place every day!

Is Ortho Clinical Diagnostics public?

Ortho Clinical Diagnostics now operates as an independent company….Ortho Clinical Diagnostics.

Type	Public
Founded	1939 Linden, New Jersey, U.S.
Headquarters	1001 US-202, Raritan, New Jersey , U.S.
Area served	Worldwide

Is Ortho Clinical Diagnostics profitable?

Consensus from 10 of the American Medical Equipment analysts is that Ortho Clinical Diagnostics Holdings is on the verge of breakeven. They expect the company to post a final loss in 2021, before turning a profit of US$438k in 2022. The company is therefore projected to breakeven around a year from now or less!

What is Ortho Clinical Diagnostics known for?

Ortho Clinical Diagnostics is a leading global provider of in vitro diagnostics. We have an established track record for providing high-quality products and services to the global clinical laboratory and immunohematology communities.

How many employees does Ortho Clinical Diagnostics have?

4,4002019
Ortho Clinical Diagnostics/Number of employees

What does Ortho Clinical Diagnostics do?

Is Ortho Clinical Diagnostics for sale?

It’s finally official! Ortho Clinical Diagnostics (OCD) will be sold to The Carlyle Group (CG: NASDAQ), an asset management firm and equity investor. The sales agreement was announced on Thursday. Carlyle will pay $4.15 billion, and the transaction is expected to close mid-year, pending regulatory approvals.

Should I buy Ortho Clinical Diagnostics stock?

The consensus among Wall Street research analysts is that investors should “buy” Ortho Clinical Diagnostics stock. View analyst ratings for Ortho Clinical Diagnostics or view top-rated stocks.

Is OCDX a good investment?

The financial health and growth prospects of OCDX, demonstrate its potential to underperform the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this stock lacks momentum and would be a lackluster choice for momentum investors.

Is OCDX a buy?

Ortho Clinical Diagnostics (NASDAQ:OCDX) Analyst Rating Information. The high price target for OCDX is $30.00 and the low price target for OCDX is $20.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Who is the owner of Ortho Clinical Diagnostics?

Private equity firm Carlyle Group, which owns Ortho-Clinical Diagnostics, is planning to take the company public through an IPO. External Website. Opens New Window

What kind of technology does Ortho Clinical Diagnostics use?

It offers chemistry and immunodiagnostics solutions including integrated chemistry systems, immunodiagnostic systems, laboratory automation, and middleware solutions, and acute kidney injury-acute renal failure testing devices and meters.

How much money does Ortho Clinical Diagnostics make?

Ortho Clinical Diagnostics’s revenue was reported to be $1.8 b in FY, 2019 which is a 0.8% increase from the previous period. Ortho Clinical Diagnostics’s current market capitalization is $5 b.

What do you need to know about an ortho employee?

Ortho employees are customer-focused professionals who exercise the highest levels of integrity. Profound Purpose. Passionate People We are responsive, visionary, and inspired to grow and succeed.